AstraZeneca easily delivered on chief executive Pascal Soriot’s pledge to deliver $45 billion in revenues by 2023, set a decade earlier as he fended off a takeover bid by Pfizer. Now, he thinks that ...
Learn more about whether IDEAYA Biosciences, Inc. or Arcus Biosciences, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.
2Division of Cellular Signaling, National Cancer Center Research Institute, Tokyo, Japan. 3Center for Cancer Genomics and Advanced Therapeutics (C-CAT), National Cancer Center, Tokyo, Japan.
This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results